Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by June 3, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders, Bain Capital and Pfizer, made false statements related to a secondary stock offering on October 16, 2023, and a proxy statement on January 18, 2024 [5]. - The secondary stock offering allowed Bain Capital to acquire shares at a discounted price before AbbVie Inc.'s acquisition announcement, which was made just 51 days later at $45 per share, nearly double the offering price [5]. - Bain Capital's discounted purchases from the offering resulted in a windfall of over $120 million when the true details were revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in this area [4].

To join the Cerevel class action, go to https://rosenlegal.com/submit-form/?case_id=37997 mailto:or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to ...

LOS ANGELES, May 19, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE) investors of a class action representing investors that bought securities between October 11, 2023 through August 1, 2024, inclusive (the "Class Period"). Cerevel investors have until June 3, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discu ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options A class action was filed against against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”), Bain Capital Investors, LLC (“Bain”) and Pfizer, Inc. (“Pfizer”) on behalf of investors that (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through Au ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) for violations of the federal securities laws on behalf of investors who: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive (the “Class ...

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. for alleged violations of federal securities laws, particularly concerning misleading statements and undisclosed material facts related to Cerevel's stock offerings and acquisition processes [6][4][7]. Group 1: Legal Allegations - The complaint alleges that the defendants made false and/or misleading statements and failed to disclose material facts during Cerevel's secondary stock offering on October 16, 2023, where shares were sold at $22.81 [6]. - Bain Capital is accused of acquiring Cerevel shares while allegedly possessing nonpublic information about AbbVie's interest in acquiring the company, which was later disclosed at a price of $45 per share [6][7]. - The January 18, 2024, Proxy statement regarding the AbbVie acquisition is claimed to have misled investors about the sales process and conflicts of interest, suggesting that Bain and Pfizer orchestrated the process to maximize profits at the expense of public shareholders [6][7]. Group 2: Class Action Details - Investors who sold or disposed of Cerevel stock between October 11, 2023, and August 1, 2024, or held shares as of January 8, 2024, may have been damaged by the defendants' actions and are encouraged to contact the law firm for legal options [1][4]. - The deadline for investors to seek the role of lead plaintiff in the federal securities class action is June 3, 2025 [4]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [8].

NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all persons or entities that: (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the “Class Period”); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merge ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period, alleging misleading statements related to a secondary stock offering and an undisclosed acquisition by AbbVie Inc. [1][5] Group 1: Lawsuit Details - The class action lawsuit targets individuals or entities that sold or held Cerevel common stock from October 11, 2023, to August 1, 2024, and those entitled to vote on the merger with AbbVie as of January 8, 2024 [1] - The lawsuit claims that during the class period, Cerevel's controlling shareholders, Bain Capital and Pfizer, made false statements regarding a secondary stock offering, which allowed Bain to acquire shares at a discounted price before AbbVie announced its acquisition of Cerevel for $45 per share, nearly double the offering price [5] - Bain Capital's discounted purchases from the offering resulted in a windfall of over $120 million when the acquisition was announced [5] Group 2: Next Steps for Investors - Investors wishing to join the class action can do so without any out-of-pocket fees through a contingency fee arrangement [2] - Interested parties can visit the provided link or contact Rosen Law Firm for more information on joining the class action [3][6] - A lead plaintiff must file a motion with the court by June 3, 2025, to represent other class members in the litigation [1][3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4]

SAN DIEGO, April 16, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”), Bain Capital Investors, LLC (“Bain”) and Pfizer, Inc. (“Pfizer”) on behalf of a class (the “Class”) consisting of all persons or entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were dam ...

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. on behalf of investors who sold or held shares during a specified period, alleging misleading statements related to a secondary stock offering and an acquisition by AbbVie Inc. [1][5] Group 1: Lawsuit Details - The lawsuit covers individuals or entities that sold or held Cerevel common stock from October 11, 2023, to August 1, 2024, and those entitled to vote on the merger with AbbVie [1] - Allegations include that Bain Capital and Pfizer orchestrated a secondary stock offering to allow Bain to acquire shares at a discounted price before AbbVie’s acquisition announcement [5] - The acquisition by AbbVie was announced at $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5] Group 2: Legal Representation - Investors may join the class action without any out-of-pocket fees through a contingency fee arrangement [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - A lead plaintiff must be appointed by June 3, 2025, to represent the interests of the class members [1][3]